Home » Stocks » ALEC

Alector, Inc. (ALEC)

Stock Price: $15.44 USD -1.35 (-8.04%)
Updated May 13, 2021 2:35 PM EDT - Market open
Market Cap 1.33B
Revenue (ttm) 18.04M
Net Income (ttm) -202.38M
Shares Out 79.39M
EPS (ttm) -2.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $15.44
Previous Close $16.79
Change ($) -1.35
Change (%) -8.04%
Day's Open 16.75
Day's Range 15.13 - 17.03
Day's Volume 297,947
52-Week Range 9.12 - 34.89

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Alector (ALEC) delivered earnings and revenue surprises of 2.94% and -35.93%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced business updates and finan...

1 week ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M...

1 month ago - GlobeNewsWire

Clovis Oncology, Inc. (NASDAQ: CLVS), Marker Therapeutics, Inc. (NASDAQ: MRKR) and Alector, Inc. (NASDAQ: ALEC) are among the biggest biotech gainers Friday. Clovis Jumps On Ovarian Cancer Data: Clovis ...

Other stocks mentioned: CLVS, MRKR
1 month ago - Benzinga

SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the first participan...

3 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that chief business offic...

3 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today provided a preview of its planned c...

4 months ago - GlobeNewsWire

Alector is a leader in neuroimmunology drug development. This has enabled the company to build a pipeline of medicines pursuing large and important markets from dementia and Alzheimer's.

4 months ago - Seeking Alpha

Alector, Inc (Nasdaq: ALEC) is a clinical-stage biopharmaceutical company focused on immuno-neurology, immune dysfunction studies related to degenerative brain disorders. Alector has 4-clinical phase th...

Other stocks mentioned: ABBV
5 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D., c...

6 months ago - GlobeNewsWire

Alector (ALEC) delivered earnings and revenue surprises of -24.07% and -22.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced corporate updates and fin...

6 months ago - GlobeNewsWire

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that an independent arbit...

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that members of the Compa...

6 months ago - GlobeNewsWire

Alector (ALEC) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that members of manage...

8 months ago - GlobeNewsWire

Baby boomers have a reputation of being old and therefore irrelevant. However, this powerful and influential generation can spark huge demand for many stocks to buy.

Other stocks mentioned: AIG, AMP, LVS, RCL, SCI, UAL, WELL ...
8 months ago - InvestorPlace

Alector (ALEC) delivered earnings and revenue surprises of -11.54% and -64.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced corporate updates and f...

9 months ago - GlobeNewsWire

Alector Looks Like A Buy After Huge Selloff

9 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D.,...

9 months ago - GlobeNewsWire

Investors appear nervous that COVID-19 precautions could create obstacles to trials evaluating its lead drug candidate.

9 months ago - The Motley Fool

SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced preliminary data from i...

9 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., July 24, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced dosing of the first pat...

9 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the company will h...

9 months ago - GlobeNewsWire

Alector (ALEC) delivered earnings and revenue surprises of -10.42% and -32.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical- stage biotechnology company pioneering immuno-neurology, today announced business highlights and...

1 year ago - GlobeNewsWire

Is (ALEC) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., March 25, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company and leader in the discovery and development of therapeutics that ha...

1 year ago - GlobeNewsWire

Alector (ALEC) delivered earnings and revenue surprises of -2.27% and -37.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., March 23, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) today announced the addition of Paula Hammond, Ph.D., to the Company’s Board of Directors. Dr. Hammond is t...

1 year ago - GlobeNewsWire

Alector (ALEC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Alector (ALEC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 year ago - Zacks Investment Research

Investors need to pay close attention to Alector (ALEC) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Alector (ALEC) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

1 year ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the U.S. Food and ...

1 year ago - GlobeNewsWire

- Total gross proceeds from the offering to Alector are approximately $240 million - Total gross proceeds from the offering to Alector are approximately $240 million

1 year ago - GlobeNewsWire

Total gross proceeds from the offering to Alector, including from the sale of the additional shares, are expected to be approximately $240 million Total gross proceeds from the offering to Alector, incl...

1 year ago - GlobeNewsWire

Public Offering of 8,350,000 Shares of Common Stock for Gross Proceeds of Approximately $208 Million Public Offering of 8,350,000 Shares of Common Stock for Gross Proceeds of Approximately $208 Million

1 year ago - GlobeNewsWire

Alector: A Promising Neuro-Immunology Pick For 2020

1 year ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it intends to offer and...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that in December 2019, ...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Alector Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that it has been selecte...

1 year ago - GlobeNewsWire

Biotech investing is risk-fraught, but for investors who make the right bets, the returns can be staggering.

Other stocks mentioned: AMGN, FULC, RARE, RDUS, SAGE, SRPT, VRTX
1 year ago - Benzinga

During its R&D day, company announced that Drs. Scheller and Südhof will support its mission to pioneer the discovery and development of transformative immune therapies for neurodegeneration During its ...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Sheh...

1 year ago - GlobeNewsWire

The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.

Other stocks mentioned: AGN, AMRN, ATNX, BHVN, CARA, GBT, ITCI ...
1 year ago - The Motley Fool

About ALEC

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that ... [Read more...]

Industry
Biotechnology
IPO Date
Feb 7, 2019
CEO
Arnon Rosenthal
Employees
181
Stock Exchange
NASDAQ
Ticker Symbol
ALEC
Full Company Profile

Financial Performance

In 2020, Alector's revenue was $21.10 million, a decrease of -0.57% compared to the previous year's $21.22 million. Losses were -$190.23 million, 80.5% more than in 2019.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Alector stock is "Strong Buy." The 12-month stock price forecast is 32.00, which is an increase of 107.25% from the latest price.

Price Target
$32.00
(107.25% upside)
Analyst Consensus: Strong Buy